Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma

Not Applicable

Active, not recruiting

Conditions: Esophageal Cancer

Interventions: Procedure: Esophagectomy
Drug: 5-fluorouracil
Drug: Cisplatin
Radiation: Radiation therapy

First Posted Date: 2017-10-11

Last Posted Date: 2024-05-23

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 240

Registration Number: NCT03306901

Locations: 🇰🇷
National Cancer Center, Goyang-si, Korea, Republic of
🇰🇷
Pusan National University Hospital, Pusan, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

and more 6 locations

5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab

Phase 3

Terminated

Conditions: Colorectal Adenocarcinoma
Stage IIIB Colorectal Cancer AJCC v7
Stage IIIC Colorectal Cancer AJCC v7
Stage III Colorectal Cancer AJCC v7
RAS Wild Type
Stage IIIA Colorectal Cancer AJCC v7
Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7

Interventions: Biological: Panitumumab
Drug: Oxaliplatin
Drug: Leucovorin Calcium
Drug: Fluorouracil
Other: Quality-of-Life Assessment
Drug: Capecitabine
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-10-03

Last Posted Date: 2020-06-11

Lead Sponsor: University of Southern California

Target Recruit Count: 4

Registration Number: NCT03300609

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

Phase 1

Terminated

Conditions: Locally Advanced Rectal Adenocarcinoma
Stage IVA Rectal Cancer AJCC v7
Stage IIIA Rectal Cancer AJCC v7
Stage IIIB Rectal Cancer AJCC v7
Stage IV Rectal Cancer AJCC v7
Stage IVB Rectal Cancer AJCC v7
Metastatic Rectal Adenocarcinoma
Rectal Adenocarcinoma
Stage III Rectal Cancer AJCC v7
Stage IIIC Rectal Cancer AJCC v7

Interventions: Drug: Capecitabine
Drug: Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Radiation: Radiation Therapy
Biological: Talimogene Laherparepvec

First Posted Date: 2017-10-03

Last Posted Date: 2024-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT03300544

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers

Phase 1

Terminated

Conditions: Digestive Cancer

Interventions: Drug: 5-Fluorouracil
Drug: L-Folinic acid
Drug: Oxaliplatin

First Posted Date: 2017-09-27

Last Posted Date: 2022-04-25

Lead Sponsor: Institut Cancerologie de l'Ouest

Target Recruit Count: 34

Registration Number: NCT03294252

Locations: 🇫🇷
ICO René Gauducheau, Saint-Herblain, France
🇫🇷
Hopital Begin, Saint-Mandé, France
🇫🇷
Centre Hospitalier Lyon Sud, Pierre-Bénite, France

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

Phase 1

Active, not recruiting

Conditions: GastroEsophageal Cancer

Interventions: Drug: Irinotecan
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-Fluorouracil
Drug: Paclitaxel
Radiation: Radiation Therapy
Drug: Carboplatin

First Posted Date: 2017-09-12

Last Posted Date: 2022-10-05

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 25

Registration Number: NCT03279237

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Aflibercept
Drug: Irinotecan
Drug: folinic acid (dl racemic)
Drug: 5Fluorouracil
Drug: 5-FU

First Posted Date: 2017-09-12

Last Posted Date: 2023-04-13

Lead Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Target Recruit Count: 170

Registration Number: NCT03279289

Locations: 🇪🇸
Spanish Cooperative Group for Digestive Tumour Therapy (TTD), Madrid, Spain

First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

Phase 3

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Panitumumab
Drug: Irinotecan
Drug: Oxaliplatin
Drug: l-leucovorin
Drug: 5-fluorouracil

First Posted Date: 2017-07-27

Last Posted Date: 2023-01-05

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 435

Registration Number: NCT03231722

Locations: 🇮🇹
Fondazione IRCCS Istituto Oncologico Veneto, Padova, Italy
🇮🇹
A.O. Universitaria Pisana - Pisa (Pi) Oncologia Medica, Pisa, Italy
🇮🇹
Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy

and more 1 locations

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Phase 2

Withdrawn

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Irinotecan
Drug: Oxaliplatin
Drug: Levoleucovorin
Drug: 5-FU
Drug: GM-CSF
Drug: IL-2

First Posted Date: 2017-07-19

Last Posted Date: 2018-03-27

Lead Sponsor: Fujian Cancer Hospital

Registration Number: NCT03222089

Locations: 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

Phase 3

Active, not recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: Placebo
Biological: Pembrolizumab
Drug: Cisplatin
Drug: Docetaxel
Drug: Capecitabine
Drug: Oxaliplatin
Drug: 5-fluorouracil
Drug: Leucovorin

First Posted Date: 2017-07-18

Last Posted Date: 2024-10-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1007

Registration Number: NCT03221426

Locations: 🇺🇸
Fox Chase Cancer Center ( Site 0006), Philadelphia, Pennsylvania, United States
🇨🇦
Cross Cancer Institute ( Site 0033), Edmonton, Alberta, Canada
🇨🇦
Jewish General Hospital ( Site 0034), Montreal, Quebec, Canada

and more 168 locations

PEN-866 in Patients With Advanced Solid Malignancies

Phase 1

Conditions: Adenocarcinoma of the Pancreas
Gastroesophageal Junction Adenocarcinoma
Small Cell Lung Carcinoma
Solid Tumor
Solid Carcinoma
Small-cell Lung Cancer
Squamous Cell Carcinoma of the Vulva
Gastric Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Pancreatic Adenocarcinoma

Interventions: Drug: PEN-866 Sodium
Drug: Niraparib
Drug: fluorouracil
Drug: Folinic acid

First Posted Date: 2017-07-18

Last Posted Date: 2022-02-17

Lead Sponsor: Tarveda Therapeutics

Target Recruit Count: 340

Registration Number: NCT03221400

Locations: 🇺🇸
Florida Cancer Specialists - North, Saint Petersburg, Florida, United States
🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇺🇸
Florida Cancer Specialists - East, West Palm Beach, Florida, United States

and more 13 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy